Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia

Zhou,Shiyong; Liu,Pengfei; Zhang,Huilai

doi:10.3892/mmr.2017.6581

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia

Authors:
- Shiyong Zhou
- Pengfei Liu
- Huilai Zhang
View Affiliations

Affiliations: Department of Lymphoma, Sino‑US Center of Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China
Published online on: May 12, 2017 https://doi.org/10.3892/mmr.2017.6581
Pages: 281-287
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is a frequently occurring malignant disease of the blood and may result from a variety of genetic disorders. The present study aimed to identify the underlying mechanisms associated with the therapeutic effects of decitabine and cytarabine on AML, using microarray analysis. The microarray datasets GSE40442 and GSE40870 were downloaded from the Gene Expression Omnibus database. Differentially expressed genes (DEGs) and differentially methylated sites were identified in AML cells treated with decitabine compared with those treated with cytarabine via the Linear Models for Microarray Data package, following data pre‑processing. Gene Ontology (GO) analysis of DEGs was performed using the Database for Annotation, Visualization and Integrated Analysis Discovery. Genes corresponding to the differentially methylated sites were obtained using the annotation package of the methylation microarray platform. The overlapping genes were identified, which exhibited the opposite variation trend between gene expression and DNA methylation. Important transcription factor (TF)‑gene pairs were screened out, and a regulated network subsequently constructed. A total of 190 DEGs and 540 differentially methylated sites were identified in AML cells treated with decitabine compared with those treated with cytarabine. A total of 36 GO terms of DEGs were enriched, including nucleosomes, protein‑DNA complexes and the nucleosome assembly. The 540 differentially methylated sites were located on 240 genes, including the acid‑repeat containing protein (ACRC) gene that was additionally differentially expressed. In addition, 60 TF pairs and overlapped methylated sites, and 140 TF‑pairs and DEGs were screened out. The regulated network included 68 nodes and 140 TF‑gene pairs. The present study identified various genes including ACRC and proliferating cell nuclear antigen, in addition to various TFs, including TATA‑box binding protein associated factor 1 and CCCTC‑binding factor, which may be potential therapeutic targets of AML.

View Figures

View References

1	Taga T, Tomizawa D, Takahashi H and Adachi S: Acute myeloid leukemia in children: Current status and future directions. Pediatr Int. 58:71–80. 2016. View Article : Google Scholar : PubMed/NCBI
2	Kadia TM, Ravandi F, Cortes J and Kantarjian H: New drugs in acute myeloid leukemia. Ann Oncol. 27:770–778. 2016. View Article : Google Scholar : PubMed/NCBI
3	Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
4	Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015. View Article : Google Scholar : PubMed/NCBI
5	Burnett A, Wetzler M and Löwenberg B: Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 29:487–494. 2011. View Article : Google Scholar : PubMed/NCBI
6	Marcucci G, Haferlach T and Döhner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol. 29:475–486. 2011. View Article : Google Scholar : PubMed/NCBI
7	Meyer SC and Levine RL: Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol. 15:e382–e394. 2014. View Article : Google Scholar : PubMed/NCBI
8	Cancer Genome Atlas Research Network. Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, et al: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 368:2059–2074. 2013. View Article : Google Scholar : PubMed/NCBI
9	Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, et al: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 481:506–510. 2012. View Article : Google Scholar : PubMed/NCBI
10	Roboz GJ: Current treatment of acute myeloid leukemia. Curr Opin Oncol. 24:711–719. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wang ES: Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program. 2014:14–20. 2014.PubMed/NCBI
12	Curran MP: Decitabine: A review of its use in older patients with acute myeloid leukaemia. Drugs Aging. 30:447–458. 2013. View Article : Google Scholar : PubMed/NCBI
13	Klco JM, Spencer DH, Lamprecht TL, Sarkaria SM, Wylie T, Magrini V, Hundal J, Walker J, Varghese N, Erdmann-Gilmore P, et al: Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood. 121:1633–1643. 2013. View Article : Google Scholar : PubMed/NCBI
14	Gautier L, Cope L, Bolstad BM and Irizarry RA: affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
15	Durinck S, Spellman PT, Birney E and Huber W: Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat Protoc. 4:1184–1191. 2009. View Article : Google Scholar : PubMed/NCBI
16	Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article32004. View Article : Google Scholar : PubMed/NCBI
17	Wang D, Yan L, Hu Q, Sucheston LE, Higgins MJ, Ambrosone CB, Johnson CS, Smiraglia DJ and Liu S: IMA: An R package for high-throughput analysis of Illumina's 450K Infinium methylation data. Bioinformatics. 28:729–730. 2012. View Article : Google Scholar : PubMed/NCBI
18	Sherman BT, da Huang W, Tan Q, Guo Y, Bour S, Liu D, Stephens R, Baseler MW, Lane HC and Lempicki RA: DAVID Knowledgebase: A gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics. 8:4262007. View Article : Google Scholar : PubMed/NCBI
19	Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D: The human genome browser at UCSC. Genome Res. 12:996–1006. 2002. View Article : Google Scholar : PubMed/NCBI
20	Daskalakis M, Blagitko-Dorfs N and Hackanson B: Decitabine. Small Molecules in Oncology Berlin Heidelberg: Springer; pp. 131–157. 2010, View Article : Google Scholar
21	Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM and Lübbert M: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 23:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
22	Löwenberg B: Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 121:26–28. 2013. View Article : Google Scholar : PubMed/NCBI
23	Momparler RL: Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia. Exp Hematol Oncol. 2:202013. View Article : Google Scholar : PubMed/NCBI
24	Hu S, Wan J, Su Y, Song Q, Zeng Y, Nguyen HN, Shin J, Cox E, Rho HS, Woodard C, et al: DNA methylation presents distinct binding sites for human transcription factors. Elife. 2:e007262013. View Article : Google Scholar : PubMed/NCBI
25	Egger G, Liang G, Aparicio A and Jones PA: Epigenetics in human disease and prospects for epigenetic therapy. Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
26	Robertson KD: DNA methylation and human disease. Nat Rev Genet. 6:597–610. 2005. View Article : Google Scholar : PubMed/NCBI
27	Feinberg AP: Phenotypic plasticity and the epigenetics of human disease. Nature. 447:433–440. 2007. View Article : Google Scholar : PubMed/NCBI
28	Reik W: Stability and flexibility of epigenetic gene regulation in mammalian development. Nature. 447:425–432. 2007. View Article : Google Scholar : PubMed/NCBI
29	Weaver IC, Hellstrom IC, Brown SE, Andrews SD, Dymov S, Diorio J, Zhang TY, Szyf M and Meaney MJ: The methylated-DNA binding protein MBD2 enhances NGFI-A (egr-1)-mediated transcriptional activation of the glucocorticoid receptor. Philos Trans R Soc Lond B Biol Sci. 369:pii: 20130513. 2014. View Article : Google Scholar : PubMed/NCBI
30	Robertson KD and Wolffe AP: DNA methylation in health and disease. Nat Rev Genet. 1:11–19. 2000. View Article : Google Scholar : PubMed/NCBI
31	Hu Y, Liu F, Lin IY, Gao GF and Zhu B: Dissemination of the mcr-1 colistin resistance gene. Lancet Infect Dis. 16:146–147. 2016. View Article : Google Scholar : PubMed/NCBI
32	Lewis JD, Meehan RR, Henzel WJ, Maurer-Fogy I, Jeppesen P, Klein F and Bird A: Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA. Cell. 69:905–914. 1992. View Article : Google Scholar : PubMed/NCBI
33	Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL and Schübeler D: Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet. 37:853–862. 2005. View Article : Google Scholar : PubMed/NCBI
34	Cokus SJ, Feng S, Zhang X, Chen Z, Merriman B, Haudenschild CD, Pradhan S, Nelson SF, Pellegrini M and Jacobsen SE: Shotgun bisulphite sequencing of the Arabidopsis genome reveals DNA methylation patterning. Nature. 452:215–219. 2008. View Article : Google Scholar : PubMed/NCBI
35	Nestheide S, Bridge JA, Barnes M, Frayer R and Sumegi J: Pharmacologic inhibition of epigenetic modification reveals targets of aberrant promoter methylation in Ewing sarcoma. Pediatr Blood Cancer. 60:1437–1446. 2013. View Article : Google Scholar : PubMed/NCBI
36	Ben Abdelali R, Roggy A, Leguay T, Cieslak A, Renneville A, Touzart A, Banos A, Randriamalala E, Caillot D, Lioure B, et al: SET-NUP214 is a recurrent γδ lineage-specific fusion transcript associated with corticosteroid/chemotherapy resistance in adult T-ALL. Blood. 123:1860–1863. 2014. View Article : Google Scholar : PubMed/NCBI
37	Manodoro F, Marzec J, Chaplin T, Miraki-Moud F, Moravcsik E, Jovanovic JV, Wang J, Iqbal S, Taussig D, Grimwade D, et al: Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood. 123:2066–2074. 2014. View Article : Google Scholar : PubMed/NCBI
38	Buchi F, Spinelli E, Masala E, Gozzini A, Sanna A, Bosi A, Ferrari G and Santini V: Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine. Leuk Res. 36:607–618. 2012. View Article : Google Scholar : PubMed/NCBI